Print Page     Close Window     

SEC Filings

SERES THERAPEUTICS, INC. filed this Form 8-K on 09/04/2018
Entire Document

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 30, 2018, the Board of Directors (the “Board”) of the Company increased the size of the Board from eight to nine directors, and elected Meryl Zausner as a Class II director of the Company. Ms. Zausner has been appointed to serve on the Audit Committee of the Board (the “Audit Committee”).

Ms. Zausner will participate in the Company’s standard compensation program for non-employee directors, including an annual retainer of $35,000, an annual retainer for service on the Audit Committee of $7,500, and an initial award of an option to purchase 30,000 shares of the Company’s common stock (the “Initial Award”). The Initial Award has an exercise price equal to $8.47, the closing price per share of the Company’s common stock on the date of grant, and will vest and become exercisable in equal installments on each of the first four anniversaries of the date of grant, subject to continued service on the Board through each such vesting date. Ms. Zausner has also entered into the Company’s standard indemnification agreement for directors and officers.

© Seres Therapeutics. All Rights Reserved.